This is a working overview of WADA prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
==== Reticular region ==== The reticular region lies deep in the papillary region and is usually much thicker. It is composed of dense irregular connective tissue and receives its name from the dense concentration of collagenous, elastic, and reticular fibers that weave throughout it. These protein fibers give the dermis its properties of strength, extensibility, and elasticity. Also located within the reticular region are the roots of the hair, sweat glands, sebaceous glands, receptors, nails, and blood vessels.
The "inert" or noble gas elements (helium, neon, argon, krypton, xenon and radon) are composed of lone atoms as their smallest discrete unit, but the other isolated chemical elements consist of either molecules or networks of atoms bonded to each other in some way. Identifiable molecules compose familiar substances such as water, air, and many organic compounds like alcohol, sugar, gasoline, and the various pharmaceuticals. However, not all substances or chemical compounds consist of discrete molecules, and indeed most of the solid substances that make up the solid crust, mantle, and core of the Earth are chemical compounds without molecules. These other types of substances, such as ionic compounds and network solids, are organized in such a way as to lack the existence of identifiable molecules per se. Instead, these substances are discussed in terms of formula units or unit cells as the smallest repeating structure within the substance. Examples of such substances are mineral salts (such as table salt), solids like carbon and diamond, metals, and familiar silica and silicate minerals such as quartz and granite. One of the main characteristics of a molecule is its geometry often called its structure. While the structure of diatomic, triatomic or tetra-atomic molecules may be trivial, (linear, angular pyramidal etc.) the structure of polyatomic molecules, that are constituted of more than six atoms (of several elements) can be crucial for its chemical nature.
Those with more neutrons in the nucleus than those required for stability are known as proton-deficient, and tend to be most easily produced in a nuclear reactor. The majority of radiopharmaceuticals are based on proton deficient isotopes, with technetium-99m being the most commonly used medical isotope, and therefore nuclear reactors are the prime source of medical radioisotopes. Those with fewer neutrons in the nucleus than those required for stability are known as neutron-deficient, and tend to be most easily produced using a proton accelerator such as a medical cyclotron.
is the radius of curvature of the menisci at the elongated ends of the droplet. This process is simple and consistently results in two droplets of equal volume. The conventional method of splitting an existing droplet by simply turning the splitting electrodes on and off produces new droplets of relatively equal volume. However, the new droplets formed by the conventional method show considerable difference in volume. This difference is caused by local perturbations due to the rapid mass transport. Even though the difference is negligible in some applications, it can still pose a problem in applications that are highly sensitive to variations in volume, such as immunoassays and DNA amplification. To overcome the limitation of the conventional method, an existing droplet can be split by gradually changing the potential of the electrodes at the splitting region instead of simply switching them on and off. Using this method, a noticeable improvement in droplet volume variation, from around 10% variation in volume to less than 1% variation in volume, has been reported.
Sources: en.wikipedia.org
The 2007 pet food recalls involved the massive recall of many brands of cat and dog foods beginning in March 2007. The recalls came in response to reports of renal failure in pets consuming mostly wet pet foods made with wheat gluten from a single Chinese company, beginning in February 2007. After more than three weeks of complaints from consumers, the recall began voluntarily with the Canadian company Menu Foods on March 16, 2007, when a company test showed sickness and death in some of the test animals. Overall, several major companies recalled more than 100 brands of pet foods, with most of the recalled product coming from Menu Foods. The contaminant was identified as melamine, which had been added as an adulterant to simulate a higher protein content. In the United States, there has been extensive media coverage of the recall. There have been calls for government regulation of pet foods, which had previously been self-regulated by pet food manufacturers. The economic impact on the pet food market has been extensive, with Menu Foods losing roughly $30 million alone from the recall.
The siliceous frustules of diatoms accumulate in fresh and brackish wetlands and lakes. Some peats and mucks contain a sufficient abundance of frustules such that they can be mined. Most of Florida's diatomaceous earths have been found in the muck of wetlands or lakes. The American Diatomite Corporation, from 1935 to 1946, refined a maximum of 145 tons per year from their processing plant near Clermont, Florida. Muck from several locations in Lake County, Florida was dried and burned (calcined) to produce the diatomaceous earth. It was formerly extracted from Lake Mývatn in Iceland. The commercial deposits of diatomite are restricted to Tertiary or Quaternary periods. Older deposits from as early as the Cretaceous Period are known, but are of low quality. Diatomite deposits rich in fossils have been located in New Zealand, but mining of the Foulden Maar deposits on an industrial scale, for conversion to animal feed, has drawn strong opposition.
=== 2018–present: Cool Blue Jewels and Pink Python === On February 9, 2018, Riff Raff and DJ Afterthought released the album Cool Blue Jewels with features from Wiz Khalifa, Chevy Woods, Jimmy Wopo, Young Buck and Project Pat, among others. On November 9, 2018, Riff Raff released a mixtape titled Tangerine Tiger with guest appearances from Z-Ro, Lil Tracy, Ricki Rich among others. On April 12, 2019, Riff Raff released his third studio album titled Pink Python with guest appearances from Chief Keef, J-Dawg, and Killah Priest. Riff Raff premiered his single "Jazzmine" with the Houston Chronicle, a remake of "A Whole New World" from Aladdin featuring Iliana Eve, Jonathan Hay, Aneesa Badshaw, Ranna Royce and others. On October 25, 2019, Riff Raff released his fourth studio album titled Cranberry Vampire, with appearances from Simon Rex, Andy Milonakis, Chief Keef, and others.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.